CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock

Recruiting now · Phase 4 · Has a placebo group

Conditions studied: Shock, Cardiogenic

In brief

The investigators are interested in determining if there is a meaningful benefit from the use of medications purported to increase the pumping function of the heart (i.e. inotropes) among critically ill patients admitted to the Cardiac Intensive Care Unit (CICU). To do this, the investigators will conduct a multi-centre, double blind, randomized control trial with patients who are deemed to require these medications by their treating physician to one of the two most commonly used agents in Canada (Milrinone or Dobutamine) or placebo. Each patient will be closely monitored by their healthcare team. The dose of medication will be adjusted according to each patients' clinical status. After 12 hours, the participants will move to open label treatment and any continued use of inotropes will be at the discretion of their treating physician.

Key facts

Study ID
NCT05267886
Run by
Ottawa Heart Institute Research Corporation
People needed
346
Starts
2022-03-05
Expected to finish
2026-12-01
Last updated by the study team
2026-05-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.